Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, vol.395, pp.497-506, 2020. ,
Clinical characteristics of coronavirus disease 2019 in China, China Medical Treatment Expert Group for Covid, vol.382, pp.1708-1720, 2020. ,
A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, vol.579, pp.270-273, 2020. ,
Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, COVID-19 Lombardy ICU Network, vol.323, pp.1574-1581, 2020. ,
Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis, 2020. ,
High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Obesity, 2020. ,
A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med, vol.382, pp.1787-1799, 2020. ,
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries, Diabetes Metab. Syndr, vol.14, pp.241-246, 2020. ,
A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19, 2020. ,
, , 2020.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02525126
Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Natl. Sci. Rev, 2020. ,
Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med, vol.8, pp.420-422, 2020. ,
The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis, 2020. ,
Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis.-ciaa248, 2020. ,
Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19), Front Immunol, vol.11, p.827, 2020. ,
Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16 + monocytes in severe pulmonary syndrome patients of a new coronavirus, 2020. ,
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19, Nat. Med, 2020. ,
Heightened innate immune responses in the respiratory tract of COVID-19 patients, Cell Host Microbe, 2020. ,
Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern. Med, vol.13, 2020. ,
Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease, 2020. ,
Prognostic value of C-reactive protein in patients with COVID-19, 2020. ,
The potential role of IL-6 in monitoring severe case of coronavirus disease, 2019. ,
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, vol.395, pp.1054-1062, 2020. ,
Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, 2020. ,
Adjuvant corticosteroid therapy for critically ill patients with COVID-19, 2020. ,
SARS: systematic review of treatment effects, PLoS Med, vol.3, p.343, 2006. ,
Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, Saudi Critical Care Trial Group, vol.197, pp.757-767, 2018. ,
, Clinical management of severe acute respiratory infection when COVID-19 is suspected, infection-is-suspected, WHO, 2020.
Brigham and Women's Hospital COVID-19 clinical guidelines, 2020. ,
, Nonsteroidal anti-inflammatory drugs (NSAIDs) and serious infectious complications -Information Point, 2019.
Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy, Int. J. Infect. Dis, vol.17, pp.792-798, 2013. ,
The cytokine storm of severe influenza and development of immunomodulatory therapy, Cell. Mol. Immunol, vol.13, pp.3-10, 2016. ,
Cytokine release syndrome, J. Immunother. Cancer, vol.6, p.56, 2018. ,
Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report, Ann. Oncol, 2020. ,
Effective treatment of severe COVID-19 patients with Tocilizumab, Proc Natl Acad Sci, 2020. ,
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation, Blood, vol.112, pp.3073-3081, 2008. ,
, Roivant announces development of anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19, Roivant Sciences, 2020.
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, vol.395, pp.30-31, 2020. ,
TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib, J. Microbiol. Immunol. Infect, 2020. ,
Intravenous immunoglobulin therapy in rheumatic diseases, Nat. Rev. Rheumatol, vol.7, pp.349-359, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02455562
Update on the use of immunoglobulin in human disease: A review of evidence, J. Allergy Clin. Immunol, vol.139, issue.3S, pp.1-46, 2017. ,
High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019, Open Forum Infect. Dis, vol.7, p.102, 2020. ,
Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study, 2020. ,
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19, J. Infect. Published, 2020. ,
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?, Nat. Rev. Immunol, vol.13, pp.176-189, 2013. ,
IVIG-mediated effector functions in autoimmune and inflammatory diseases, Int. Immunol, vol.29, pp.491-498, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01723555
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?, Trends Pharmacol. Sci, vol.25, pp.306-310, 2004. ,
Tackling difficult Staphylococcus aureus infections: antibodies show the way, Cell Host Microbe, vol.20, pp.555-557, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01398083
Antibody responses to SARS-CoV-2 in patients with COVID-19, Nat. Med, 2020. ,
Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients, Emerg. Infect. Dis, vol.26, 2020. ,
Reinfection could not occur in SARS-CoV-2 infected rhesus macaques, 2020. ,
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, Convalescent Plasma Study Group, vol.211, pp.80-90, 2015. ,
Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antivir. Ther. (Lond.), vol.23, pp.617-622, 2018. ,
Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann. Intern. Med, vol.145, pp.599-609, 2006. ,
Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest, vol.144, pp.464-473, 2013. ,
Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses, Trends Immunol, vol.41, pp.355-359, 2020. ,
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. USA, vol.101, pp.2536-2541, 2004. ,
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med, vol.3, p.237, 2006. ,
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor, Cell Mol Immunol, 2020. ,
A highly conserved cryptic epitope in the receptorbinding domains of SARS-CoV-2 and SARS-CoV, Science, vol.368, pp.630-633, 2020. ,
A human monoclonal antibody blocking SARS-CoV-2 infection, Nat Commun, vol.11, p.2251, 2020. ,
Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis.ciaa344, 2020. ,
Profiling early humoral response to diagnose novel coronavirus disease (COVID-19), Clin. Infect. Dis.ciaa310, 2020. ,
China puts 245 COVID-19 patients on convalescent plasma therapy, 2020. ,
Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, vol.323, pp.1582-1589, 2020. ,
Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. USA, vol.117, pp.9490-9496, 2020. ,
Takeda initiates development of a plasma-derived therapy for COVID-19, 2020. ,
Grifols announces formal collaboration with US government to produce the first treatment specifically targeting COVID-19, 2020. ,
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial, 2020. ,
Human FOXP3 + regulatory T cell heterogeneity and function in autoimmunity and cancer, Immunity, vol.50, pp.302-316, 2019. ,
The yin and yang of regulatory T cells in infectious diseases and avenues to target them, Cell. Microbiol, vol.19, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01510317
In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression, J. Exp. Med, vol.206, pp.751-760, 2009. ,
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism, Nat. Med, vol.24, pp.1005-1014, 2018. ,
Revisiting IL-2: biology and therapeutic prospects, Sci. Immunol, vol.3, p.1482, 2018. ,
Treating human autoimmunity: current practice and future prospects, Sci. Transl. Med, vol.4, pp.125-126, 2012. ,
FDA accepts IND for NK cell therapy CYNK-001 to treat patients with COVID-19, 2020. ,
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect, 2020. ,
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, 2020. ,
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-271, 2020. ,
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, vol.6, p.16, 2020. ,
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, 2020. ,
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med. Mal. Infect, 2020. ,
Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N. Engl. J. Med, 2020. ,